Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
You may also be interested in...
Korea FDA Targets 30 Firms For Offering Rebates; Orders 21 Drugs Off The Market For 30 Days
KFDA has imposed fines and ordered some drugs off the market for 30 days as penalties to pharma companies involved in rebates; more such actions are planned.
Korea Novel Drug Prices 50% Of Similar Countries, But A Window Opens For Reform
MNC pharma association in Korea lobbies for delinking generic drugs from new drug pricing in year ahead.
Korea Novel Drug Prices 50% Of Similar Countries, But A Window Opens For Reform
MNC pharma association in Korea lobbies for delinking generic drugs from new drug pricing in year ahead.